propranolol has been researched along with cifenline in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Faller, B; Trunzer, M; Zimmerlin, A | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aupetit, JF; Bertrix, L; Faucon, G; Lancon, JP; Lang, J; Timour, Q | 1 |
| Brugada, J; Canovas, M; Cazes, M; Massé, C; Puech, P; Romero-Ayala, LC; Sassine, A | 1 |
| Kogaki, S; Kurotobi, S; Nasuno, S; Ohta, M; Okabe, H; Ozono, K; Sakai, N; Takahashi, K; Taniike, M; Wada, K | 1 |
| Imai, T; Kajimoto, K; Kasanuki, H; Minami, Y | 1 |
| Kishita, Y; Kono, Y; Miyauchi, A; Murayama, K; Okazaki, Y; Omika, N; Osaka, H; Sato, T; Shimozawa, H; Takeda, A; Yada, Y; Yamagata, T | 1 |
13 other study(ies) available for propranolol and cifenline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
Topics: Chromatography, Liquid; Drug Design; Humans; Likelihood Functions; Microsomes, Liver; Pharmacokinetics; Tandem Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of isoproterenol and propranolol on pharmacologically induced depression of intraventricular conduction.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Depression, Chemical; Dogs; Electrocardiography; Female; Heart Conduction System; Imidazoles; In Vitro Techniques; Isoproterenol; Male; Neural Conduction; Propranolol; Sympathetic Nervous System; Time Factors | 1989 |
Evidence for a class 4 effect of cibenzoline "in vivo".
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Dogs; Electrocardiography; Female; Heart Conduction System; Imidazoles; Kinetics; Male; Propranolol | 1987 |
A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Chromosomes, Human, Pair 12; Drug Therapy, Combination; Glutamic Acid; Glutamine; Humans; Imidazoles; Infant; Intracellular Signaling Peptides and Proteins; Male; Mutation, Missense; Noonan Syndrome; Propranolol; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatases; Treatment Outcome | 2005 |
Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Echocardiography, Doppler; Female; Humans; Imidazoles; Lidocaine; Linear Models; Male; Middle Aged; Propranolol; Prospective Studies; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Pressure; Verapamil | 2010 |
A Case of Infantile Mitochondrial Cardiomyopathy Treated with a Combination of Low-Dose Propranolol and Cibenzoline for Left Ventricular Outflow Tract Stenosis.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Constriction, Pathologic; Humans; Imidazoles; Infant, Newborn; Male; NADH Dehydrogenase; Propranolol; Ventricular Function, Left | 2022 |